ABSTRACT
We surveyed patients the next morning after in-laboratory polysomnography (PSG) to compare the first night effect (FNE) and reverse first night effect (RFNE) in different sleep disorders. A questionnaire was given to 852 patients with insomnia (nâ¯=â¯171), restless legs syndrome (nâ¯=â¯186), obstructive sleep apnea (nâ¯=â¯369), simple snoring (nâ¯=â¯54), REM sleep behavior disorder (nâ¯=â¯39), and hypersomnia (nâ¯=â¯33). FNE was seen in 48.9%, 30.5% slept as usual, and 20.6% had RFNE. The highest incidences of FNE were seen in OSA, simple snoring, hypersomnia, and in men. We propose to use these findings as a reference when interpreting nocturnal in-laboratory PSG results.
Subject(s)
Polysomnography/psychology , Sleep Wake Disorders/diagnosis , Sleep Wake Disorders/psychology , Sleep/physiology , Surveys and Questionnaires , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Polysomnography/methods , Polysomnography/trends , REM Sleep Behavior Disorder/diagnosis , REM Sleep Behavior Disorder/physiopathology , REM Sleep Behavior Disorder/psychology , Retrospective Studies , Sleep Apnea, Obstructive/diagnosis , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/psychology , Sleep Initiation and Maintenance Disorders/diagnosis , Sleep Initiation and Maintenance Disorders/physiopathology , Sleep Initiation and Maintenance Disorders/psychology , Sleep Wake Disorders/physiopathology , Snoring/diagnosis , Snoring/physiopathology , Snoring/psychology , Time FactorsABSTRACT
The efficacy and the adverse effects of intravenous iron formulas have been well established. However, there are few reports of anaphylaxis of ferric carboxymaltose (FCM). A man received intravenous FCM for the treatment of restless legs syndrome. The FCM gave rise to angioedema, urticaria, chest tightness, sinus tachycardia, and hypotension. In the end, epinephrine and dexamethasone resolved the symptoms. The findings were consistent with anaphylactic hypersensitivity reaction from FCM. We need to be careful when we administer FCM in clinics.
